News Release

SOLVD Health to Present at William Blair’s Innovator Series: Life Science Tools and Diagnostics

SAN DIEGO–(BUSINESS WIRE)–SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, announced today that its Founder and CEO, Dr. Keri Donaldson, will provide a company update and participate in a virtual fireside chat at William Blair’s Innovator Series: Life Science Tools and Diagnostics.

Dr. Donaldson’s presentation will take place on Tuesday, December 17, 2024, from 1:00 p.m. to 1:45 p.m. ET. The session will include a company update followed by a Q&A with William Blair’s Diagnostics Analyst, Andrew Brackmann. Together, they will discuss SOLVD Health’s advancements, ongoing initiatives, and the company’s vision for transforming health outcomes through innovative genetic and AI-driven tools.

William Blair’s Innovator Series is a premier virtual event that highlights some of the most dynamic and fast-growing private companies in the life science tools and diagnostics space.

The event provides investors with the opportunity to learn directly from industry leaders about cutting-edge advancements shaping the future of healthcare.

Event Details:

  • Date: Tuesday, December 17, 2024
  • Time: 1:00 p.m. – 1:45 p.m. ET
  • Location: Virtual

“We’re excited to share SOLVD Health’s progress and innovative approach to enhancing personalized health outcomes,” said Dr. Keri Donaldson. “This series is an important platform for showcasing the transformative potential of precision health solutions.”

For more information about the William Blair Innovator Series, visit the event page link.

About SOLVD Health
SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, SOLVD Health enables individuals and their providers to make better decisions about their health and the health of their families. SOLVD Health accomplishes this by translating complex biological signals into actionable patient data that can point the way to better health.

Media Contact:
Valerie Melucci
Vice President of Marketing, SOLVD Health
pr@solvdhealth.com

Investors:
Mark Hazeltine
Chief Financial Officer, SOLVD Health
investors@solvdhealth.com

SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

SOLVD Health Publishes Peer-Reviewed Framework to Advance Clinical Use of Genomic Data

December 15, 2025 — SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility.

read more
SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response

SOLVD Health Advances Development of Novel Test to Optimize GLP-1 Therapeutic Response

December 9, 2025 – SOLVD Health is launching two studies to validate our GLP‑1 patient stratification platform, bringing precision medicine to obesity and type 2 diabetes care. “As the worldwide prevalence of obesity and type 2 diabetes continues to grow, the need for more targeted, personalized treatment methods becomes increasingly critical,” Dr. Keri Donaldson, Founder and President, SOLVD Health.

read more
SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

May 12, 2025 – SOLVD Health appoints diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company’s continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform.

read more